impact of glp-1 drugs on industries The Agonists the MedTech Sector: Articulating a continued value proposition for devices Upgrading from Overweight: The Effects

Obesity and Type 2 diabetes represent global health challenges, and there is an unmet need for long-lasting and effective pharmacotherapies

We are thrilled to welcome back two returning guests, Dr

drugs like Ozempic).

Despite these encouraging findings, further research is still needed to understand more thoroughly the mechanisms by which GLP-1RAs may mediate stroke protection specifically in the human diabetic brain.

Primary outcomes included changes in TTR, INR, and INR recheck frequency

This review examines the biological mechanisms underlying GLP-1 RA therapy in MASLD/MASH, analyzes the mechanistic distinctions between mono-, dual-, and triple agonists, and synthesizes current clinical evidence supporting their utilization in individuals with this condition.